Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, dal 1982 In collaborazione con l'Associazione Culturale Pediatri

Ricerca

PDF MeBrain

Performance del QuantiFERON-TB Gold In-Tube test nei bambini

QuantiFERON-TB Gold In-Tube test performance in a paediatric population

Flavio Storelli, Chiara Tersigni, Elisabetta Venturini, Maurizio de Martino, Luisa Galli, Elena Chiappini
Dipartimento di Scienze della Salute, AOU “Anna Meyer”, Università di Firenze

Marzo 2020

Abstract
Background - The performance of QuantiFERON-TBGold In-Tube (QTF-IT) in children is under debate, especially under 5 years of age and for the interpretation of discordant results between QFT-IT and Tuberculin-Skin-Test (TST).
Materials and Methods - Children consecutively referred to our Unit between 2010-2017 for suspected tuberculosis infection (TB) were enrolled. All children underwent clinical evaluation, TST and QFT-IT. Finally, the sensitivity of QFT-IT and TST in active TB cases and the risk factors associated with discordant TST+/QFT-IT- results were assessed.
Results - In this study 4,631 children (477 under two years of age, 1,318 between 2-4 years and 2,836 between 5-18 years) were enrolled. Overall, 205 active TB cases were reported (83 microbiologically confirmed, among them 63 with positive QFT-IT and 60 with positive TST). Considering microbiologically confirmed active TB children, a high sensitivity of QFT-IT was observed (95.0%; 95% CI: 85.4-100; n = 19) among children between 2-4 years of age and in those between 5-18 years (89.1%; 95% CI: 79.2-99.2; n = 33) while sensitivity was suboptimal in children younger than 2 years (84.6%; 95% CI: 65.0-100; n = 11). Independent risk factors associated with discordant TST+/QFT-IT- results, in LTBI children investigated with both tests, were: previous BCG vaccination (aOR: 2.18; 95% CI: 1.33-3.58; p = 0.002), age < 2 years vs 5-18 years (aOR: 7.54; 95% CI: 2.52-22.59; p < 0.0001), and age 2-4 years vs 5-18 years (aOR: 4.63; 95% CI: 2.66-8.06; p < 0.0001) and investigation for screening rather than for contact with a suspected or confirmed case (aOR: 3.58; 95% CI: 2.30-5.59; p < 0.0001).
Conclusions - The data suggest that QFT-IT might be used as unique assay in children over 2 years of age investigated for recent immigration/adoption screening and in case of recent low risk TB contact. This approach could considerably reduce the number of children undergoing pharmacological treatment. Conversely, both tests are recommended in case of strong clinical suspicious or high risk TB contact in children less than 5 years of age, in order to avoid misdiagnosis.
Riassunto

Obiettivo - La performance del QuantiFERON-TB Gold In-Tube (QFT-IT) nel bambino è ancora oggetto di dibattito, soprattutto per quanto riguarda i bambini sotto i 5 anni di età e l’interpretazione dei risultati discordanti tra QFT-IT e il test di intradermoreazione secondo Mantoux (Tuberculin Skin Test o TST).
Materiali e Metodi - Sono stati inclusi nello studio tutti i bambini (0-18 anni) afferenti presso il Servizio di malattie infettive pediatriche dell’AOU Meyer, Firenze, per sospetta infezione tubercolare (TB) nel periodo 2010-2017. Tutti i bambini sono stati sottoposti a valutazione clinica, TST e QFT-IT. È stata infine calcolata la sensibilità del QFT-IT e del TST nei casi di TB attiva e valutati i fattori di rischio associati a risultati discordanti TST+/QFT-IT-.
Risultati - Sono stati arruolati 4631 bambini (477 sotto i due anni di età, 1318 tra 2-4 anni e 2836 tra i 5-18 anni) di cui 2099 (57,1%) maschi. In totale 205 sono stati i casi nei quali è stata posta diagnosi di TB attiva (83 confermati microbiologicamente, dei quali 63 con QFT-IT positivo e 60 con TST positivo). Considerando il sottogruppo dei bambini con TB attiva microbiologicamente confermata è stata osservata un’elevata sensibilità del QFT-IT (95,0%; 95% IC: 85,4-100; n = 19) nei bambini tra 2-4 anni di età e in quelli fra 5-18 anni (89,1%; 95% IC: 79,2-99,2; n = 33), mentre la sensibilità risultava ancora subottimale nei bambini di età inferiore ai due anni (84,6%; 95% IC: 65,0-100; n = 11). Fattori di rischio indipendenti per discordanza TST+/QFT-IT- in bambini con TB latente (LTBI) sono risultati essere: una precedente vaccinazione con BCG (aOR: 2,18; 95% IC: 1,33-3,58; p = 0,002), età < 2 anni vs 5-18 anni (aOR: 7,54; 95% IC: 2,52-22,59; p < 0,0001), età 2-4 anni vs 5-18 anni (aOR: 4,63; 95% IC: 2,66-8,06; p < 0,0001) e essere stati testati per screening rispetto che per contatto con caso sospetto o confermato di TB (aOR: 3,58; 95% IC: 2,30-5,59; p < 0,0001).
Conclusione - I nostri risultati suggeriscono che il QFT-IT potrebbe essere usato come unico test per la diagnosi immunologica in bambini di età superiore a 2 anni indagati per screening per recente immigrazione/adozione o per recente contatto a basso rischio con TB e questo approccio potrebbe considerevolmente ridurre il numero di bambini sottoposti a trattamento farmacologico. Al contrario, entrambi i test sono raccomandati in caso di forte sospetto clinico o contatto ad alto rischio con TB nei bambini di età inferiore a 5 anni, al fine di evitare diagnosi errate.

Contenuto riservato

Per leggere l'articolo è necessario effettuare il login.

Per l'acquisto del singolo articolo scrivi a abbonamenti@medicoebambino.com (la mail si prepara da sola con gli estremi dell'articolo); se accedi, la richiesta parte con un click.

Bibliografia

  1. World Health Organization. Global tuberculosis report 2018. Genova, 2018.
  2. World Health Organization. Latent TB infection: updated and consolidated guidelines for programmatic management. Genova, 2018.
  3. World Health Organization. Implementing the end TB strategy: the essentials. Genova, 2015.
  4. Pearce EC, Woodward JF, Nyandiko WM, Vreeman RC, Ayaya SO. A systematic review of clinical diagnostic systems used in the diagnosis of tuberculosis in children. AIDS Res Treat 2012;401896. doi: 10.1155/2012/401896.
  5. Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D. Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2011;15(8):1018-32. doi: 10.5588/ijtld.10.0631.
  6. Chiappini E, Bonsignori F, Mazzantini R, et al. Interferon-gamma release assay sensitivity in children younger than 5 years is insufficient to replace the use of tuberculin skin test in Western Countries. Pediatr Infect Dis J 2014;33:1291-3. doi: 10.1097/INF.0000000000000432.
  7. Kay AW, Islam SM, Wendorf K, Westenhouse J, Barry PM. Interferon gamma release assay performance for tuberculosis in childhood. Pediatrics 2018;141. doi: 10.1542/peds.2017-3918.
  8. Bastian I, Coulter C; National Tuberculosis Advisory Committee (NTAC). Position statement on interferon-γ release assays for the detection of latent tuberculosis infection. Commun Dis Intell Q Rep 2017;41(4):E322-36.
  9. Pourakbari B, Yousefi K, Mahmoudi S, Sadeghi RH, Mamishi S. Evaluation of the QuantiFERON®-TB Gold In-Tube assay and tuberculin skin test for the diagnosis of latent tuberculosis infection in an Iranian referral hospital. Infect Disord Drug Targets 2019;19(2):141-4. doi: 10.2174/1871526518666180228164036.
  10. American Academy of Pediatric. Tuberculosis. In: Kimberlin DW, Brady MT, Kackson MA, et al. Red Book: 2018 report of the Committee on Infectious Diseases. 31th ed. Elk Grove Village, IL: American Academy of Pediatrics 2018:829-53.
  11. American Academy of Pediatrics. Tuberculosis. In: Kimberlin DW, Brady MT, Kackson MA, et al. Red Book: 2015 report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics 2015:804-830.
  12. National Institute for Health and Care Excellence. Tuberculosis. NICE 2016 (ultimo accesso: 30 ottobre 2018).
  13. American Academy of Pediatrics. Tuberculosis. In: Pickering LK (ed). Red book: report of the Committee on infectious diseases. 28th edition. American Academy of Pediatrics, Elk Grove Village 2009;680-701.
  14. Kampmann B, Whittaker E, Williams A, et al. Interferon-gamma release assays do not identify more children with active tuberculosis than the tuberculin skin test. Eur Respir J 2009;33:1374-82. doi: 10.1183/09031936.00153408.
  15. Cellestis/Qiagen. QuantiFERON® TB Gold (In-Tube Method) Package Insert. Australia, 2006 (ultimo accesso: 30 ottobre 2018).
  16. Mastrolia MV, Sollai S, Totaro C, et al. Utility of tuberculin skin test and IGRA for tuberculosis screening ininternationally adopted children: Retrospective analysis from a single center in Florence, Italy. Travel Med Infect Dis 2019;28:64-7. doi: 10.1016/j.tmaid.2018.07.009.
  17. Debord C, De Lauzanne A, Gourgouillon N, et al. Interferon-gamma release assay performance for diagnosing tuberculosis disease in 0- to 5-year-old children. Pediatr Infect Dis J 2011;30(11):995-7. doi: 10.1097/INF.0b013e3182272227.
  18. Petrucci R, Lombardi G, Corsini I, et al. Quantiferon-TB Gold In-Tube improves tuberculosis diagnosis in children. Pediatr Infect Dis J 2017;36(1):44-9. doi: 10.1097/INF.0000000000001350.
  19. Velasco-Arnaiz E, Soriano-Arandes A, Latorre I, et al. Performance of tuberculin skin tests and interferon-γ release assays in children younger than 5 years. Pediatr Infect Dis J 2018;37(12):1235-41. doi: 10.1097/INF.0000000000002015.
  20. Bielecka T, Augustynowicz-Kopeć E, Gonerko P, et al. Recommendations for the management of tuberculosis in children - KOMPASS TB. Part 1: Tuberculosis prevention. Adv Respir Med 2018;86(3):149-57. doi: 10.5603/ARM.2018.0023.
  21. Lombardi G, Petrucci R, Corsini I, et al. Quantitative analysis of gamma interferon release assay response in children with latent and active tuberculosis. J Clin Microbiol 2018;56(2):1-9. doi: 10.1128/JCM.01360-17.
  22. Sali M, Buonsenso D, Goletti D, et al. Accuracy of QuantiFERON TB Gold test for tuberculosis diagnosis in children. PLoS One 2015;10(10):1-13. doi: 10.1371/journal.pone.0138952.
  23. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of bacille Calmette Guérin vaccination on tuberculin skin test measurements. Thorax 2002;57(9):804-9. doi: 10.1136/thorax.57.9.804.
  24. Mancuso JD, Mody RM, Olsen CH, Harrison LH, Santosham M, Aronson NE. The long-term effect of bacille Calmette-Guérin vaccination on tuberculin skin testing: a 55-year follow-up study. Chest 2017;152(2):282-94. doi: 10.1016/j.chest.2017.01.001.
  25. Tsolia MN, Mavrikou M, Critselis E, et al. Whole blood interferon-γ release assay is a useful tool for the diagnosis of tuberculosis infection particularly among bacille Calmette Guérin-vaccinated children. Pediatr Infect Dis J 2010;29(12):1137-40. doi: 10.1097/INF.0b013e3181ebfe8a.